

Subject: Medication Administration – All Providers
Narcan® Nasal Spray Administration

I. Class

Narcotic antagonist.

II. Indications

Suspected opioid overdose with decreased level of consciousness and/or bradypnea (slow breathing) or apnea.

III. Therapeutic Effects

- A. Naloxone competes for opiate receptors in the brain and displaces opioid molecules from opiate receptors.
- B. It can reverse opioid overdose.

IV. Contraindications

A. Absolute

- 1. Known hypersensitivity.
- 2. An advanced airway is in place, and the patient is being adequately ventilated.
- 3. Infants < 30 days.

B. Relative

None.

V. Administration and Dosage

The route for ALL BLS Providers will only include Intranasal (IN) Narcan® (Naloxone) Nasal Spray.

A. Adult:

- 1. 4mg intranasal via auto device.
- 2. May be repeated every 2-3 minutes if no improvement.

B. Pediatric (>30 days of age):

- 1. 4mg intranasal via auto device.
- 2. May be repeated every 2-3 minutes if no improvement.

VI. Special Information/Side Effects

- A. Acute withdrawal symptoms
- B. Include nausea and vomiting,
- C. Hypotension

VII. Base Orders

Standing Order if no contraindications exist.